Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 85
Filter
1.
World Neurosurg ; 146: 80-84, 2021 02.
Article in English | MEDLINE | ID: mdl-33130141

ABSTRACT

BACKGROUND: Radiation therapy for intracranial lesions is constrained by dose to neurologic organs at risk. CASE DESCRIPTION: We report 2 cases, a newly diagnosed chondrosarcoma and a previously irradiated meningioma, with tumors that abutted the optic chiasm following subtotal resection. Definitive radiotherapy would have required either undercoverage of the tumor or treatment of the chiasm with doses posing an unacceptable risk of blindness. Therefore, the patients underwent open surgery with placement of an abdominal fat autograft to provide space between the tumor and the optic structures at risk. Patients received definitive fractionated stereotactic radiotherapy. For each patient, we retrospectively compared the treated plan (with fat autograft) to a second plan generated using the pre-autograft imaging, maintaining similar tumor coverage. For the chondrosarcoma, the fat autograft reduced the optic chiasm maximum dose by 21% (70.4 Gy to 55.3 Gy). For the reirradiated peri-optic meningioma, the optic chiasm maximum dose was reduced by 10% (50.8 Gy to 45.9 Gy), the left optic nerve by 17% (48.9 Gy to 40.4 Gy), and the right optic nerve by 30% (32.3 Gy to 22.6 Gy). CONCLUSIONS: We demonstrate the utility of abdominal fat autograft placement to maximize coverage of tumor while minimizing dose to intracranial organs at risk.


Subject(s)
Abdominal Fat/transplantation , Brain Neoplasms/radiotherapy , Optic Chiasm/radiation effects , Radiation Injuries/prevention & control , Radiosurgery/methods , Adult , Autografts , Chondrosarcoma/radiotherapy , Female , Humans , Male , Meningeal Neoplasms/radiotherapy , Meningioma/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Organs at Risk , Radiometry , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods
2.
Int J Radiat Oncol Biol Phys ; 110(1): 87-99, 2021 05 01.
Article in English | MEDLINE | ID: mdl-29534899

ABSTRACT

PURPOSE: Dosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation. METHODS AND MATERIALS: Eligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION). RESULTS: Thirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in <1% RION risks include 12 Gy in 1 fraction (which is greater than our recommendation of 10 Gy in 1 fraction), 20 Gy in 3 fractions, and 25 Gy in 5 fractions. Omitting multi-fraction data (and thereby eliminating uncertainties associated with dose conversions), a single-fraction dose of 10 Gy was associated with a 1% RION risk. Insufficient details precluded modeling of NTCP risks after prior radiation therapy. CONCLUSIONS: Optic apparatus NTCP and tolerance doses after single- and multi-fraction stereotactic radiosurgery are presented. Additional standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses and better define RION NTCP after SRS/fSRS.


Subject(s)
Optic Nerve/radiation effects , Organs at Risk/radiation effects , Radiosurgery/adverse effects , Adenoma/radiotherapy , Blindness/etiology , Cavernous Sinus , Craniopharyngioma/radiotherapy , Humans , Maximum Tolerated Dose , Meningeal Neoplasms/radiotherapy , Meningioma/radiotherapy , Models, Biological , Models, Theoretical , Optic Chiasm/radiation effects , Pituitary Neoplasms/radiotherapy , Radiation Dose Hypofractionation , Radiation Tolerance , Radiosurgery/methods , Radiotherapy Dosage , Re-Irradiation , Skull Base Neoplasms/radiotherapy , Visual Acuity/radiation effects , Visual Fields/radiation effects
3.
Acta Oncol ; 59(10): 1257-1262, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32762400

ABSTRACT

PURPOSE: Radiotherapy-related visual decline is a significant concern in survivors of childhood cancer; however, data establishing the dose-response relationship between dose to the optic apparatus and visual acuity decline in children are sparse. We aimed to determine this relationship in a cohort of children treated with proton therapy. MATERIAL AND METHODS: We identified 458 children with 875 eyes at risk treated with proton therapy for intracranial malignancy between December 2006 and September 2018. Eyes were considered at risk if either the ipsilateral optic nerve or optic chiasm received ≥30 GyRBE to 0.1 cm3. Kaplan-Meier and Normal Tissue Complication Probability modeling was used to establish the relationship between radiotherapy dose and risk of visual decline. RESULTS: Excluding children with tumor progression, no patient experienced complete vision loss. The actuarial 5-year rate of any visual acuity decline was 2.6% (95% confidence interval [CI]: 1.5%-4.6%). The dose to 0.1 cm3 of the ipsilateral optic nerve or optic chiasm resulting in a 1%, 5%, and 10% risk of acuity decline were 52.7 GyRBE, 56.6 GyRBE, and 58.3 GyRBE. Visual decline was only seen in children with primary tumors of the optic pathway or suprasellar region. CONCLUSIONS: Visual acuity decline following radiotherapy for intracranial malignancies in children is rare. A dose of approximately 56 GyRBE to 0.1 cm3 results in an approximately 5% risk of visual acuity decline for children with suprasellar or optic pathway tumors. A dose to 0.1 cm3 of 56 GyRBE appears to be safe for children with tumors elsewhere in the brain.


Subject(s)
Brain Neoplasms/radiotherapy , Proton Therapy/adverse effects , Visual Acuity/radiation effects , Child , Humans , Optic Chiasm/radiation effects , Optic Nerve/radiation effects , Organs at Risk , Survivors
4.
Br J Radiol ; 93(1107): 20190028, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31322969

ABSTRACT

OBJECTIVE: To assess the radiation-induced optic neuropathy (RION) prevalence, following high dose pencil beam scanning proton therapy (PBSPT) to skull base and head and neck (H&N) tumours. METHODS: Between 1999 and 2014, 216 adult patients, median age 47 years (range, 18-77), were treated with PBS PT for skull base or H&N malignancies, delivering ≥45 GyRBE to the optic nerve(s) (ON) and/or optic chiasma (OC). The median administered dose to the planning target volume was 74.0 GyRBE (range, 54.0-77.4). The median follow-up was 5.3 years (range, 0.8-15.9). RESULTS: RION was observed in 14 (6.5%) patients at a median time of 13.2 months (range, 4.8-42.6) following PBSPT. Most (92.9%) of RION were symptomatic. Most affected patients (11/14; 79%) developed unilateral toxicity. Grade 4, 3, 2 and 1 toxicity was observed in 10, 2, 1 and 1 patients, respectively. On univariate analyses, age (<70 vs ≥70 years; p < 0.0001), hypertension (p = 0.0007) and tumour abutting the optic apparatus (p = 0.012) were associated with RION. OC's V60 GyRBE was of border line significance (p = 0.06). None of the other evaluated OC-ON dose/volume metrics (Dmax, Dmean, V40-60) were significantly associated with this complication. CONCLUSION: These data suggest that high-dose PBS PT for skull base and H&N tumours is associated with a low prevalence of RION. Caution should be however exercised when treating elderly/hypertensive patients with tumours abutting the optic apparatus. ADVANCES IN KNOWLEDGE: This is the first study reporting the risk of developing RION following proton therapy with PBS technique, demonstrating the safety of this treatment.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Optic Nerve Diseases/etiology , Optic Nerve/radiation effects , Proton Therapy/adverse effects , Radiation Injuries/complications , Skull Base Neoplasms/radiotherapy , Adolescent , Adult , Age Factors , Aged , Analysis of Variance , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/surgery , Humans , Hypertension/complications , Middle Aged , Optic Chiasm/radiation effects , Optic Nerve Diseases/epidemiology , Optic Nerve Diseases/pathology , Prevalence , Proton Therapy/methods , Radiotherapy Dosage , Radiotherapy, Adjuvant , Risk Factors , Skull Base Neoplasms/pathology , Skull Base Neoplasms/surgery , Young Adult
5.
Radiat Oncol ; 14(1): 201, 2019 Nov 12.
Article in English | MEDLINE | ID: mdl-31718650

ABSTRACT

BACKGROUND: This retrospective German and Italian multicenter analysis aimed to compare the role of normofractionated stereotactic radiotherapy (nFSRT) to CyberKnife-based hypofractionated stereotactic radiotherapy (CK-hFSRT) for skull base meningiomas. METHODS: Overall, 341 patients across three centers were treated with either nFSRT or CK-hFSRT for skull base meningioma. Treatment planning was based on computed tomography (CT) and magnetic resonance imaging (MRI) following institutional guidelines. Most nFSRT patients received 33 × 1.8 Gy, and most CK-hFSRT patients received 5 × 5 Gy. The median follow-up time was 36 months (range: 1-232 months). RESULTS: In the CK-hFSRT group, the 1-, 3-, and 10-year local control (LC) rates were 99.4, 96.8, and 80.3%, respectively. In the nFSRT group, the 1-, 3-, and 10-year LC rates were 100, 99, and 79.1%, respectively. There were no significant differences in LC rates between the nFSRT and CK-hFSRT groups (p = 0.56, hazard ratio = 0.76, 95% confidence interval, 0.3-1.9). In the CK-hFSRT group, only one case (0.49%) of severe toxicity (CTCAE 4.0 ≥ 3) was observed. In the nFSRT group, three cases (2.1%) of grade III toxicity were observed. CONCLUSION: This analysis of pooled data from three centers showed excellent LC and low side effect rates for patients treated with CK-hFSRT or nFSRT. The efficacy, safety, and convenience of a shortened treatment period provide a compelling case for the use of CK-hFSRT in patients with moderate size skull base meningioma and provided that OAR constraints are met.


Subject(s)
Meningeal Neoplasms/radiotherapy , Meningioma/radiotherapy , Radiation Dose Hypofractionation , Radiosurgery/methods , Radiotherapy/methods , Skull Base Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Algorithms , Brain Stem/radiation effects , Dose Fractionation, Radiation , Germany , Humans , Italy , Magnetic Resonance Imaging , Middle Aged , Models, Statistical , Optic Chiasm/radiation effects , Optic Nerve/radiation effects , Radiometry , Reproducibility of Results , Retrospective Studies , Tomography, X-Ray Computed , Treatment Outcome
6.
Acta Oncol ; 58(12): 1765-1774, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31429359

ABSTRACT

Purpose: Pediatric craniopharyngioma, adult base-of-skull sarcoma and chordoma cases are all regarded as priority candidates for proton therapy. In this study, a dosimetric comparison between volumetric modulated arc therapy (VMAT) and intensity modulated proton therapy (IMPT) was first performed. We then investigated the impact of physical and biological uncertainties. We assessed whether IMPT plans remained dosimetrically superior when such uncertainty estimates were considered, especially with regards to sparing organs at risk (OARs).Methodology: We studied 10 cases: four chondrosarcoma, two chordoma and four pediatric craniopharyngioma. VMAT and IMPT plans were created according to modality-specific protocols. For IMPT, we considered (i) variable RBE modeling using the McNamara model for different values of (α/ß)x, and (ii) robustness analysis with ±3 mm set-up and 3.5% range uncertainties.Results: When comparing the VMAT and IMPT plans, the dosimetric advantages of IMPT were clear: IMPT led to reduced integral dose and, typically, improved CTV coverage given our OAR constraints. When physical robustness analysis was performed for IMPT, some uncertainty scenarios worsened the CTV coverage but not usually beyond that achieved by VMAT. Certain scenarios caused OAR constraints to be exceeded, particularly for the brainstem and optical chiasm. However, variable RBE modeling predicted even more substantial hotspots, especially for low values of (α/ß)x. Variable RBE modeling often prompted dose constraints to be exceeded for critical structures.Conclusion: For base-of-skull and pediatric craniopharyngioma cases, both physical and biological robustness analyses should be considered for IMPT: these analyses can substantially affect the sparing of OARs and comparisons against VMAT. All proton RBE modeling is subject to high levels of uncertainty, but the clinical community should remain cognizant possible RBE effects. Careful clinical and imaging follow-up, plus further research on end-of-range RBE mitigation strategies such as LET optimization, should be prioritized for these cohorts of proton patients.


Subject(s)
Chordoma/radiotherapy , Craniopharyngioma/radiotherapy , Organs at Risk/radiation effects , Pituitary Neoplasms/radiotherapy , Radiotherapy, Intensity-Modulated/methods , Sarcoma/radiotherapy , Skull Base Neoplasms/radiotherapy , Adult , Brain Stem/radiation effects , Child , Humans , Linear Energy Transfer , Optic Chiasm/radiation effects , Optic Nerve/radiation effects , Radiation Injuries/prevention & control , Radiotherapy Dosage , Relative Biological Effectiveness , Uncertainty
7.
J Med Imaging Radiat Oncol ; 63(5): 657-664, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31173469

ABSTRACT

INTRODUCTION: Sparing of the organs at risk (OARs) is a crucial task in daily radiotherapy practice. Irradiation of the optic chiasm (OC) results in radiation-induced optic neuropathy (RION). The structure of the OC is complex, and OC morphology can vary in axial images. Therefore, a standard atlas can result in inaccurate descriptions of OC morphology in different patients. The aim of our study was to provide a guide based on computed tomography (CT) for the delineation of different types of OC. METHODS: Thirty-six patients were selected to participate in our study. These patients underwent CT analysis of the brain, head and neck regions in a supine position. Axial images 3 mm in thickness were obtained at 3-mm intervals. A magnetic resonance imaging (MRI) study was also performed using the same set-up. The OC was then delineated. The contours were revised by three neuroradiologists and nine radiation oncologists with > 5 years of expertise. RESULTS: Three types of OC were distinguished by magnetic resonance (MR). The location and boundaries of normal, prefixed and postfixed chiasms were developed with a CT-based atlas. Discrepancies were observed in the delineation of the prefixed and postfixed OC. CONCLUSIONS: Our guide allows improved definitions of the anatomical boundaries for different types of OC. Our experience could provide useful information for radiation oncologists in daily practice.


Subject(s)
Cranial Irradiation , Magnetic Resonance Imaging , Optic Chiasm/anatomy & histology , Optic Chiasm/diagnostic imaging , Radiotherapy Planning, Computer-Assisted , Tomography, X-Ray Computed , Anatomic Landmarks , Anatomic Variation , Brain Neoplasms/radiotherapy , Humans , Optic Chiasm/radiation effects , Organ Sparing Treatments , Organs at Risk/radiation effects , Patient Positioning
8.
Br J Radiol ; 92(1099): 20190170, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31067077

ABSTRACT

OBJECTIVE: Avoidance of radiation-induced optic neuropathy (RION) from stereotactic radiosurgery (SRS) requires precise anatomical localization; however, no prior studies have characterized the physiologic motion of the optic chiasm. We measured the extent of chiasm motion and its impact on SRS dose. METHODS: In this cross-sectional study, serial MRI was performed in multiple planes in 11 human subjects without optic pathway abnormalities to determine chiasm motion across time. Subsequently, the measured displacement was applied to the hypothetical chiasm dose received in 11 patients treated with SRS to a perichiasmatic lesion. RESULTS: On sagittal images, the average anteroposterior chiasm displacement was 0.51 mm [95% confidence interval (CI) 0.27 - 0.75 mm], and the average superior-inferior displacement was 0.48 mm (95% CI 0.22 - 0.74 mm). On coronal images, the average superior-inferior displacement was 0.42 mm (95% CI 0.13 - 0.71 mm), and the average lateral displacement was 0.75 mm (95% CI 0.42 - 1.08 mm). In 11 patients who underwent SRS to a perichiasmatic lesion, the average displacements increased the maximum chiasm dose (Dmax) by a mean of 14 % (range 6-23 %; p < 0.001). CONCLUSION: Average motion of the optic chiasm was approximately 0.50-0.75 mm, which increased chiasm Dmax by a mean of 14%. In the occasional patient with higher-than-average chiasm motion in a region of steep dose gradient, the increase in chiasm Dmax and risk of RION could be even larger. Similarly, previously reported chiasm dose constraints may underestimate the true dose received during radiosurgery. ADVANCES IN KNOWLEDGE: To limit the risk of RION, clinicians may consider adding a 0.50-0.75 mm expansion to the chiasm avoidance structure.


Subject(s)
Brain Neoplasms/radiotherapy , Optic Chiasm/diagnostic imaging , Optic Chiasm/physiology , Optic Nerve Diseases/prevention & control , Radiation Injuries/prevention & control , Radiosurgery/methods , Cross-Sectional Studies , Humans , Magnetic Resonance Imaging/methods , Motion , Optic Chiasm/radiation effects , Organs at Risk , Radiotherapy Dosage , Retrospective Studies
9.
Technol Cancer Res Treat ; 17: 1533033818802804, 2018 01 01.
Article in English | MEDLINE | ID: mdl-30343652

ABSTRACT

PURPOSE: The study was aimed to compare hybrid arc and volumetric-modulated arc therapy treatment plans for fractionated stereotactic radiotherapy of brain tumors. METHODS: Treatment plans of 22 patients were studied. Hybrid arc and volumetric-modulated arc therapy plans were generated using Brainlab iPlanDose and Varian Eclipse treatment planning systems, respectively, with 6 MV photon beams on a Varian TrueBeam STx linear accelerator (Palo Alto, CA). Prescription dose was 54 Gy. The fractionation was 1.8 Gy per fraction and 30 fractions in total, or 2 Gy per fraction and 27 fractions in total. Planning target volume ranged from 2.4 to 28.6 cm3. Dose conformity index, gradient index, homogeneity index, and maximum doses in organs at risk were compared. Wilcoxon signed rank test was used to determine statistical significance in paired comparison. RESULTS: Conformity indexes of hybrid arc and volumetric-modulated arc therapy plans are 1.10 ± 0.10 and 1.14 ± 0.07, respectively ( P = .4); gradient indexes are 5.02 ± 1.20 and 5.64 ± 1.28, respectively ( P = .0001); homogeneity indexes are 1.02 ± 0.01 and 1.05 ± 0.01, respectively ( P = .0001); brainstem maximum doses are 53.87 ± 1.63 Gy and 54.06 ± 3.17 Gy, respectively ( P = .1); and optic chiasm maximum doses are 53.86 ± 1.28 Gy and 53.95 ± 1.81, respectively ( P = .4). The monitor unit efficiencies of hybrid arc and volumetric-modulated arc therapy plans are 2.57 ± 0.25 MU/cGy and 2.68 ± 0.24 MU/cGy, respectively ( P = .2). The differences of conformity index, gradient index, and homogeneity index between hybrid arc and volumetric-modulated arc therapy plans are small: 0.08 ± 0.05, 0.65 ± 0.46, and 0.02 ± 0.01, respectively. The maximum doses in organs at risks are similar between hybrid arc and volumetric-modulated arc therapy plans. Hybrid arc and volumetric-modulated arc therapy plans, which have similar monitor unit efficiencies, present similar dosimetric results in the fractionated intracranial radiotherapy.


Subject(s)
Brain Neoplasms/radiotherapy , Dose Fractionation, Radiation , Radiosurgery/methods , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Intensity-Modulated/methods , Brain Neoplasms/pathology , Brain Stem/radiation effects , Humans , Optic Chiasm/radiation effects , Radiotherapy Dosage
10.
Int J Radiat Oncol Biol Phys ; 101(4): 854-859, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29730064

ABSTRACT

PURPOSE: To estimate the rate of and identify risk factors for vasculopathy after proton therapy in pediatric patients with central nervous system and skull base tumors. METHODS AND MATERIALS: Between 2006 and 2015, 644 pediatric patients with central nervous system and skull base tumors were treated with proton therapy at a single institution. The 3 most common histologies were craniopharyngioma (n = 135), ependymoma (n = 135), and low-grade glioma (n = 131). The median age was 7.6 years (range, 0.7-21.8 years), and the median prescribed dose was 54 cobalt gray equivalent (CGE) (range, 25.2-75.6 CGE). For this analysis, vasculopathy included asymptomatic vessel narrowing identified on imaging, transient ischemic attacks, and cerebrovascular accidents. Serious vasculopathy was defined as events resulting in permanent neurologic complications or requiring revascularization surgery. Multivariate logistic regression (MVA) was used to assess predictors of toxicity. Variables examined included age, neurofibromatosis, extent of surgical resection, chemotherapy, postoperative stroke, total prescribed dose, and dose delivered to the optic nerves, chiasm, and hypothalamus. RESULTS: With a median follow-up of 3.0 years (range, 0.1-9.6 years), the 3-year cumulative rates of any vasculopathy and serious vasculopathy were 6.4% and 2.6%, respectively. Seven children (1.2%) experienced a stroke with permanent neurologic deficits; 4 required revascularization surgery. On MVA, maximum dose to the optic chiasm ≥ 54 CGE was significantly associated with the development of any vasculopathy (13.1% vs 2.2%; P < .001); age < 5 years was also significant (8.4% vs 5.4%; P < .01). On MVA, maximum dose to the optic chiasm ≥ 54 CGE also predicted serious vasculopathy (3.8% vs 1.7%; P < .05). CONCLUSIONS: Childhood cancer survivors are at risk of vasculopathy after cranial radiation therapy. Young children and those receiving ≥54 CGE to the chiasm are at an increased risk of this toxicity. These findings suggest appropriate follow-up and screening are important in this population.


Subject(s)
Brain Neoplasms/radiotherapy , Cerebrovascular Disorders/etiology , Proton Therapy/adverse effects , Skull Base Neoplasms/radiotherapy , Adolescent , Age Factors , Cancer Survivors , Child , Child, Preschool , Craniopharyngioma/radiotherapy , Ependymoma/radiotherapy , Female , Follow-Up Studies , Glioma/radiotherapy , Humans , Infant , Ischemic Attack, Transient/etiology , Male , Optic Chiasm/radiation effects , Radiotherapy Dosage , Risk Factors , Stroke/etiology , Time Factors , Young Adult
11.
Vet Comp Oncol ; 15(4): 1295-1308, 2017 Dec.
Article in English | MEDLINE | ID: mdl-27576304

ABSTRACT

Technical advances make it possible to deliver radiation therapy for canine intracranial tumours in fewer fractions, under the assumption of equivalent tumour control. With the aim of estimating the late toxicity risk profile for various tumour sizes and locations, the present paper evaluates the normal tissue complication probability (NTCP) values for the intracranial organs at risk. By making isoeffect calculations, a new 10-fraction radiation protocol was developed with the same tumour control probability (TCP) as a currently used 20-fraction standard protocol, and complication risk profiles for brain, brainstem and optic chiasm were modelled using a representative population of 64 dogs with brain tumours. For >59% of cases, the new 10-fraction protocol yielded an acceptable, low risk estimate of late toxicity (<10%). Our calculations suggest that it may be safe to treat small to intermediate-sized tumours that are neither located near the optic chiasm nor at the brainstem with 10 daily fractions of 4.35 Gy.


Subject(s)
Brain Neoplasms/veterinary , Dog Diseases/radiotherapy , Radiotherapy/veterinary , Animals , Brain/radiation effects , Brain Neoplasms/radiotherapy , Brain Stem/radiation effects , Clinical Protocols , Dogs , Female , Male , Optic Chiasm/radiation effects , Probability , Radiation Dosage , Radiotherapy/adverse effects , Risk Assessment
12.
PLoS One ; 10(4): e0126222, 2015.
Article in English | MEDLINE | ID: mdl-25894615

ABSTRACT

BACKGROUND: Whole brain radiotherapy (WBRT) is a vital tool in radiation oncology and beyond, but it can result in adverse health effects such as neurocognitive decline. Hippocampal Avoidance WBRT (HA-WBRT) is a strategy that aims to mitigate the neuro-cognitive side effects of whole brain radiotherapy treatment by sparing the hippocampi while delivering the prescribed dose to the rest of the brain. Several competing modalities capable of delivering HA-WBRT, include: Philips Pinnacle step-and-shoot intensity modulated radiotherapy (IMRT), Varian RapidArc volumetric modulated arc therapy (RapidArc), and helical TomoTherapy (TomoTherapy). METHODS: In this study we compared these methods using 10 patient datasets. Anonymized planning CT (computerized tomography) scans and contour data based on fused MRI images were collected. Three independent planners generated treatment plans for the patients using three modalities, respectively. All treatment plans met the RTOG 0933 criteria for HA-WBRT treatment. RESULTS: In dosimetric comparisons between the three modalities, TomoTherapy has a significantly superior homogeneity index of 0.15 ± 0.03 compared to the other two modalities (0.28 ± .04, p < .005 for IMRT and 0.22 ± 0.03, p < .005 for RapidArc). RapidArc has the fastest average delivery time of 2.5 min compared to the other modalities (15 min for IMRT and 18 min for TomoTherapy). CONCLUSION: TomoTherapy is considered to be the preferred modality for HA-WBRT due to its superior dose distribution. When TomoTherapy is not available or treatment time is a concern, RapidArc can provide sufficient dose distribution meeting RTOG criteria and efficient treatment delivery.


Subject(s)
Hippocampus/radiation effects , Organ Sparing Treatments/methods , Radiotherapy, Intensity-Modulated/adverse effects , Radiotherapy, Intensity-Modulated/methods , Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Eye/radiation effects , Humans , Optic Chiasm/radiation effects , Optic Nerve/radiation effects , Radiometry , Radiotherapy Planning, Computer-Assisted , Time Factors
13.
Radiother Oncol ; 114(2): 230-8, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25701297

ABSTRACT

PURPOSE: Accurate organs at risk definition is essential for radiation treatment of brain tumors. The aim of this study is to provide a stepwise and simplified contouring guide to delineate the OARs in the brain as it would be done in the everyday practice of planning radiotherapy for brain cancer treatment. METHODS: Anatomical descriptions and neuroimaging atlases of the brain were studied. The dosimetric constraints used in literature were reviewed. RESULTS: A Computed Tomography and Magnetic Resonance Imaging based detailed atlas was developed jointly by radiation oncologists, a neuroradiologist and a neurosurgeon. For each organ brief anatomical notion, main radiological reference points and useful considerations are provided. Recommended dose-constraints both for adult and pediatric patients were also provided. CONCLUSIONS: This report provides guidelines for OARs delineation and their dose-constraints for the treatment planning of patients with brain tumors.


Subject(s)
Brain Neoplasms/radiotherapy , Brain/anatomy & histology , Brain/radiation effects , Organs at Risk/radiation effects , Radiotherapy Planning, Computer-Assisted/methods , Adult , Child , Cochlea/anatomy & histology , Cochlea/radiation effects , Female , Humans , Magnetic Resonance Imaging/methods , Male , Neuroimaging/methods , Optic Chiasm/anatomy & histology , Optic Chiasm/radiation effects , Pituitary Gland/anatomy & histology , Pituitary Gland/radiation effects , Radiation Dosage , Radiometry/methods , Tomography, X-Ray Computed/methods
14.
Radiol Med ; 120(4): 352-60, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25091709

ABSTRACT

BACKGROUND AND PURPOSE: Sparing of the organs at risk is one of the primary end-points of radiotherapy. The effects of organ-at-risk delineation on the dosimetric parameters can be critical and can influence treatment planning and outcomes. The aim of our study was to provide anatomical boundaries for the identification and delineation of the following critical organs at risk in the head and neck district: brachial plexus, cochlea, pharyngeal constrictor muscles and optic chiasm. PATIENTS AND METHODS: One patient was initially selected to elaborate our atlas. This patient was subjected to a planning computed tomography of the brain and head and neck district; axial images of 3-mm thickness at 3-mm intervals were obtained. In the same set-up a magnetic resonance imaging study was also performed. The obtained images were fused based on anatomical landmarks and used by a radiation oncologist, supported by a neuroradiologist, to provide anatomo-radiological limits for the identification of the brachial plexus, cochlea, pharyngeal constrictor muscles and optic chiasm. These limits were further verified on three consecutive patients. RESULTS: A computed tomography-based atlas was developed with definition of cranial, caudal, medial, lateral, anterior and posterior limits for each organ considered. CONCLUSIONS: This study allows improvement of definitions of anatomic boundaries for the brachial plexus, cochlea, pharyngeal constrictor muscles and optic chiasm. Our multidisciplinary experience led to the production of an institutional reference tool that could represent a useful aid for radiation oncologists in clinical practice.


Subject(s)
Brachial Plexus/diagnostic imaging , Cochlea/diagnostic imaging , Head and Neck Neoplasms/diagnostic imaging , Head and Neck Neoplasms/radiotherapy , Optic Chiasm/diagnostic imaging , Pharyngeal Muscles/diagnostic imaging , Tomography, X-Ray Computed/methods , Atlases as Topic , Brachial Plexus/radiation effects , Cochlea/radiation effects , Humans , Imaging, Three-Dimensional , Magnetic Resonance Imaging , Optic Chiasm/radiation effects , Pharyngeal Muscles/radiation effects , Reproducibility of Results
15.
Radiother Oncol ; 113(1): 72-6, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25245554

ABSTRACT

BACKGROUND AND PURPOSE: Aeration in the nasal cavity and paranasal sinus (NCPS) was investigated during the course of proton therapy (PT), and the influence of aeration on the dose distribution was determined. MATERIAL AND METHODS: Twenty patients with NCPS cancer (10 nasal cavity, 10 paranasal sinus) were analyzed. All the patients received a total proton beam irradiation dose of 38-78.4 Gray equivalents (GyE). Two to five CT examinations were performed during the course of treatment. The aeration ratio inside the cavity/sinus was calculated for each CT observation. Moreover, a simulation study supposing that the first treatment plan had been continued until the end of treatment was performed using the subsequent CT findings. RESULTS: The aeration ratio was increased in 18 patients. The largest increase was from 15% to 82%. Three patients had a simulated maximum cumulative dose in the brainstem of beyond 60 GyE, while 10 patients had a simulated maximum cumulative dose in the optic chiasm of beyond 50 GyE. The shortest simulated time period to reach the dose limitation was 21 days. CONCLUSIONS: Aeration in the NCPS is altered during the course of PT treatment and can greatly alter the dose distribution in the brainstem and optic chiasm.


Subject(s)
Air , Nose Neoplasms/radiotherapy , Proton Therapy/methods , Adult , Aged , Aged, 80 and over , Brain Stem/radiation effects , Female , Humans , Male , Middle Aged , Nasal Cavity , Optic Chiasm/radiation effects , Paranasal Sinus Neoplasms/radiotherapy , Radiotherapy Dosage , Retina/radiation effects , Retrospective Studies
16.
Eur J Ophthalmol ; 24(4): 637-40, 2014.
Article in English | MEDLINE | ID: mdl-24366773

ABSTRACT

PURPOSE: Primary malignant gliomas of the optic nerves are rare tumors of adulthood, progressing rapidly to blindness and to death within several months, regardless of the type of treatment. Recently, treatments associating radiotherapy and temozolomide have been used in other types of glioblastomas, but their impact on optic nerve malignant gliomas is not known. METHODS: This was a retrospective case series of 2 patients diagnosed with primary optic nerve and chiasm glioblastoma (GBM), treated with radiotherapy and concomitant temozolomide. RESULTS: A 74-year-old man presented with visual loss caused by an infiltrative and enhancing lesion, affecting the left optic nerve and the chiasm, subsequently confirmed as GBM World Health Organization (WHO) grade IV. The patient was treated with external conformal radiotherapy (54 Gy over 42 days) and concomitant chemotherapy with temozolomide (75 mg/m2/day), followed by 6 monthly cycles of adjuvant treatment (250 mg/day for 5 days). The second patient was a 74-year-old woman diagnosed with bilateral visual loss due to pathologically confirmed GBM (WHO grade IV). She was treated with temozolomide (220 mg/day) for 1 month, followed by radiotherapy (54 Gy over 42 days) and temozolomide chemotherapy (75 mg/m2/day). There was no adjuvant regimen. This treatment resulted in disease stabilization and partial preservation of vision during 12 months for patient 1, 8 months for patient 2. Survival after first examination was 15 and 11 months, respectively. CONCLUSIONS: Combined radiotherapy and temozolomide may be an alternative treatment in optic nerve and visual pathways primary GBM, potentially providing a longer survival.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Dacarbazine/analogs & derivatives , Glioblastoma/therapy , Optic Chiasm/pathology , Optic Nerve Neoplasms/therapy , Visual Pathways/pathology , Aged , Combined Modality Therapy , Dacarbazine/therapeutic use , Female , Glioblastoma/drug therapy , Glioblastoma/pathology , Glioblastoma/radiotherapy , Humans , Magnetic Resonance Imaging , Male , Optic Chiasm/drug effects , Optic Chiasm/radiation effects , Optic Nerve Neoplasms/drug therapy , Optic Nerve Neoplasms/pathology , Optic Nerve Neoplasms/radiotherapy , Radiotherapy, Adjuvant , Retrospective Studies , Temozolomide , Visual Pathways/drug effects , Visual Pathways/radiation effects
17.
Int J Radiat Oncol Biol Phys ; 87(3): 528-33, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-23953637

ABSTRACT

PURPOSE: To assess the long-term disease control and toxicity outcomes of fractionated stereotactic radiation therapy (FSRT) in patients with pituitary adenomas treated at the BC Cancer Agency. METHODS AND MATERIALS: To ensure a minimum of 5 years of clinical follow-up, this study identified a cohort of 76 patients treated consecutively with FSRT between 1998 and 2007 for pituitary adenomas: 71% (54/76) had nonfunctioning and 29% (22/76) had functioning adenomas (15 adrenocorticotrophic hormone-secreting, 5 growth hormone-secreting, and 2 prolactin-secreting). Surgery was used before FSRT in 96% (73/76) of patients. A median isocenter dose of 50.4 Gy was delivered in 28 fractions, with 100% of the planning target volume covered by the 90% isodose. Patients were followed up clinically by endocrinologists, ophthalmologists, and radiation oncologists. Serial magnetic resonance imaging was used to assess tumor response. RESULTS: With a median follow-up time of 6.8 years (range, 0.6 - 13.1 years), the 7-year progression-free survival was 97.1% and disease-specific survival was 100%. Of the 2 patients with tumor progression, both had disease control after salvage surgery. Of the 22 patients with functioning adenomas, 50% (11/22) had complete and 9% (2/22) had partial responses after FSRT. Of the patients with normal pituitary function at baseline, 48% (14/29) experienced 1 or more hormone deficiencies after FSRT. Although 79% (60/76) of optic chiasms were at least partially within the planning target volumes, no patient experienced radiation-induced optic neuropathy. No patient experienced radionecrosis. No secondary malignancy occurred during follow-up. CONCLUSION: In this study of long-term follow-up of patients treated for pituitary adenomas, FSRT was safe and effective.


Subject(s)
Adenoma/surgery , Pituitary Neoplasms/surgery , Radiosurgery/methods , Adenoma/metabolism , Adenoma/mortality , Adult , Aged , Aged, 80 and over , British Columbia , Disease-Free Survival , Dose Fractionation, Radiation , Female , Follow-Up Studies , Humans , Male , Middle Aged , Optic Chiasm/radiation effects , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/mortality , Radiosurgery/adverse effects , Salvage Therapy/methods , Treatment Outcome , Young Adult
18.
J Appl Clin Med Phys ; 14(4): 4313, 2013 Jul 08.
Article in English | MEDLINE | ID: mdl-23835394

ABSTRACT

An anthropomorphic head phantom, constructed from a water-equivalent plastic shell with only a spherical target, was modified to include a nonspherical target (pituitary) and an adjacent organ at risk (OAR) (optic chiasm), within 2 mm, simulating the anatomy encountered when treating acromegaly. The target and OAR spatial proximity provided a more realistic treatment planning and dose delivery exercise. A separate dosimetry insert contained two TLD for absolute dosimetry and radiochromic film, in the sagittal and coronal planes, for relative dosimetry. The prescription was 25 Gy to 90% of the GTV, with ≤ 10% of the OAR volume receiving ≥ 8 Gy for the phantom trial. The modified phantom was used to test the rigor of the treatment planning process and phantom reproducibility using a Gamma Knife, CyberKnife, and linear accelerator (linac)-based radiosurgery system. Delivery reproducibility was tested by repeating each irradiation three times. TLD results from three irradiations on a CyberKnife and Gamma Knife agreed with the calculated target dose to within ± 4% with a maximum coefficient of variation of ± 2.1%. Gamma analysis in the coronal and sagittal film planes showed an average passing rate of 99.4% and 99.5% using ± 5%/3 mm criteria, respectively. Results from the linac irradiation were within ± 6.2% for TLD with a coefficient of variation of ± 0.1%. Distance to agreement was calculated to be 1.2 mm and 1.3mm along the inferior and superior edges of the target in the sagittal film plane, and 1.2 mm for both superior and inferior edges in the coronal film plane. A modified, anatomically realistic SRS phantom was developed that provided a realistic clinical planning and delivery challenge that can be used to credential institutions wanting to participate in NCI-funded clinical trials.


Subject(s)
Phantoms, Imaging/standards , Radiosurgery/standards , Acromegaly/surgery , Adenoma/surgery , Clinical Trials as Topic , Head , Humans , Neck , Optic Chiasm/radiation effects , Organs at Risk , Pituitary Neoplasms/surgery , Quality Control , Radiotherapy Planning, Computer-Assisted/standards , Reproducibility of Results , Thermoluminescent Dosimetry
19.
Technol Cancer Res Treat ; 12(5): 403-9, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23617287

ABSTRACT

The purpose of this study was to evaluate the two functions: segment weight optimization (SWO) and segment edit (SE) in the latest XiO 4.7 radiation treatment planning system and their effect on the planning of intensity modulated radiation therapy (IMRT) for Nasopharyngeal Carcinoma (NPC). SWO first appeared in XiO 4.5 and SE in XiO 4.7. Twelve patients with NPC were selected and there were three plans for each patient: the common step-and-shoot IMRT plan (C-IMRT); S-IMRT was based on the result of C-IMRT and the plan was further optimized with SWO; F-IMRT was based on S-IMRT and the segments were edited for lowering the dose received by normal tissues. The paired plans were analyzed by comparing the total number of segments, monitor units, the homogeneity index and conformity index of the target volumes and the dose delivered to organs at risk (OAR) including spinal cord, brain stem, optic nerves, chiasm, parotids and larynx. The study exhibited that the total number of segments and monitor units of S-IMRT and F-IMRT were around 25.3%, 3.4% less than those of C-IMRT respectively. The HI and CI indexes of target volumes among three kinds of plans did not show the significant difference. The doses received by spinal cord, brain stem, parotids, larynx were decreased at S-IMRT and F-IMRT as compared to C-IMRT; the highest doses delivered to chiasm and optic nerves were S-IMRT, the next C-IMRT, the lowest F-IMRT. This study showed that the SWO function could substantially reduce the total number of segments of step-and-shoot IMRT plans and the SE function had the incredible ability to lower the dose received by normal tissues.


Subject(s)
Carcinoma/radiotherapy , Nasopharyngeal Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Intensity-Modulated/methods , Software , Algorithms , Brain Stem/radiation effects , Humans , Larynx/radiation effects , Nasopharyngeal Carcinoma , Optic Chiasm/radiation effects , Organs at Risk/radiation effects , Parotid Gland/radiation effects , Radiotherapy Dosage , Spinal Cord/radiation effects
20.
Technol Cancer Res Treat ; 12(5): 411-20, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23617288

ABSTRACT

Intensity modulated radiation therapy (IMRT) is increasingly employed in glioblastoma (GBM) treatment. The present work aimed to assess which clinical-dosimetric scenario could benefit the most from IMRT application, with respect to three-dimensional conformal radiation therapy (3D-CRT). The number of organs at risk (OARs) overlapping the planning target volume (PTV) was the parameter describing the clinical-dosimetric pattern. Based on the results, a dosimetric decision criterion to select the most appropriate treatment technique is provided. Seventeen previously irradiated patients were retrieved and re-planned with both 3D-CRT and IMRT. The prescribed dose was 60 Gy/30fx. The cases were divided into 4 groups (4 patients in each group). Each group represents the scenario where 0, 1, 2 or 3 OARs overlapped the target volume, respectively. Furthermore, in one case, 4 OARs overlapped the PTV. The techniques were compared also in terms of irradiated healthy brain tissue. The results were evaluated by paired t-test. IMRT always provided better target coverage (V95%) than 3D-CRT, regardless the clinical-dosimetric scenario: difference ranged from 0.82% (p = 0.4) for scenario 0 to 7.8% (p = 0.02) for scenario 3, passing through 2.54% (p = 0.18) and 5.93% (p = 0.08) for scenario 1 and 2, respectively. IMRT and 3D-CRT achieved comparable results in terms of dose homogeneity and conformity. Concerning the irradiation of serial-kind OARs, both techniques provided nearly identical results. A statistically significant dose reduction to the healthy brain in favor of IMRT was scored. IMRT seems a superior technique compared to 3D-CRT when there are multiple overlaps between OAR and PTV. In this scenario, IMRT allows for a better target coverage while maintaining equivalent OARs sparing and reducing healthy brain irradiation. The results from our patients dataset suggests that the overlap of three OARs can be used as a dosimetric criterion to select which patients should receive IMRT treatment.


Subject(s)
Brain Neoplasms/radiotherapy , Decision Support Techniques , Glioblastoma/radiotherapy , Organs at Risk/radiation effects , Patient Selection , Radiotherapy, Intensity-Modulated , Brain Neoplasms/surgery , Brain Stem/radiation effects , Dose Fractionation, Radiation , Glioblastoma/surgery , Humans , Optic Chiasm/radiation effects , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Adjuvant
SELECTION OF CITATIONS
SEARCH DETAIL
...